Related Experiment Videos
Approaches to antiviral chemotherapy for acute respiratory infections
1Department of Microbiology, Fukushima Medical College, Japan.
Abstract:
The causative agents of acute respiratory infections (ARI) in infants and children are mostly thought to be viruses. Some ARI in adult patients may be caused by bacteria but most often the causes are virus infections. When ARI affect immunocompromised patients or the elderly the mortality rates are significantly higher than in immunocompetent individuals. Many types of viruses cause ARI. Among them, influenza viruses A and B and respiratory syncytial virus (RSV) are thought to be the most important because of the severity of illness after infection and their high communicability in the human population. Recently, several novel antiviral drugs against ARI have been developed and some are proceeding in clinical trials. This review covers current investigations into antiviral compounds targeted at several points in the virus life-cycle. This includes PM-523, which broadly inhibits ortho- and paramyxo-viruses, two neuraminidase inhibitors for influenza virus, neutralizing antibody to RSV and chimeric soluble ICAM-1-IgA molecules targeted against rhinoviruses.
Insights
Novel antiviral drugs are being developed to combat acute respiratory infections (ARI) caused by viruses like influenza and RSV. This review examines new compounds targeting various stages of viral replication to treat these common infections.
Area of Science:
- Virology and Infectious Diseases
- Pharmacology and Drug Development
Background:
- Acute respiratory infections (ARI) are primarily viral, posing significant risks, especially to infants, children, the elderly, and immunocompromised individuals.
- Influenza viruses (A and B) and respiratory syncytial virus (RSV) are key pathogens due to disease severity and high transmissibility.
Purpose of the Study:
- To review current research on novel antiviral compounds for treating viral ARI.
- To highlight therapeutic strategies targeting different viral life-cycle stages.
Main Methods:
- Review of recent investigations into antiviral drug development.
- Focus on compounds targeting specific viruses and viral mechanisms, including broad-spectrum inhibitors, neuraminidase inhibitors, neutralizing antibodies, and receptor antagonists.
Main Results:
- Several promising antiviral agents are under investigation, with some in clinical trials.
- Examples include PM-523 (broad-spectrum antiviral), neuraminidase inhibitors (influenza), RSV-neutralizing antibodies, and ICAM-1-IgA (rhinoviruses).
Conclusions:
- Development of novel antiviral therapies offers new hope for managing severe viral ARI.
- Targeting diverse viral replication points provides a multi-pronged approach to combatting respiratory viruses.